Tumor-Suppressing Effects of miR-141 in Human Osteosarcoma

Cell Biochemistry and Biophysics

Volumn 69, Issue 2, 2014, Pages 319-325

  Xu, Haidong ^a   Mei, Qiang ^b   Xiong, Chengjie ^c   Zhao, Jianning ^a  

^a NANJING UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Human osteosarcoma; miR 141; Osteosarcoma therapy; ZEB1; ZEB2

Indexed keywords

3' UNTRANSLATED REGION; ANTISENSE OLIGONUCLEOTIDE; HOMEODOMAIN PROTEIN; MICRORNA; MIRN141 MICRORNA, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DOWN REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PATHOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; OSTEOSARCOMA; REPRESSOR PROTEINS; SEQUENCE ALIGNMENT; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84901234896     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9801-7     Document Type: Article

References (38)

1. Mirabello, L., Troisi, R. J., & Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer, 115(7), 1531-1543.
2. Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 20(3), 776-790.
3. Lewis, V. O. (2009). What's new in musculoskeletal oncology. Journal of Bone and Joint Surgery American Volume, 91(6), 1546-1556.
4. Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., et al. (2005). Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology, 23(9), 2004-2011.
5. Cho, Y., Jung, G. H., Chung, S. H., Kim, J. Y., Choi, Y., & Kim, J. D. (2011). Long-term survivals of stage IIb osteosarcoma: A 20-year experience in a single institution. Clinics in Orthopedic Surgery, 3(1), 48-54.
6. Tsuchiya, H., Tomita, K., Mori, Y., Asada, N., Morinaga, T., Kitano, S., et al. (1998). Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Research, 18(1B), 657-666.
7. Bolling, T., Schuller, P., Distelmaier, B., Schuck, A., Ernst, I., Gosheger, G., et al. (2008). Perioperative high-dose rate brachytherapy using a bendy applicator (flab): Treatment results of 74 patients. Anticancer Research, 28(6B), 3885-3890.
8. Kim, V. N., Han, J., & Siomi, M. C. (2009). Biogenesis of small RNAs in animals. Nature Reviews Molecular Cell Biology, 10(2), 39-126.
9. Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136(2), 215-233.
10. Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes & Development, 20(5), 515-524.
11. Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120(1), 15-20.
12. Griffiths-Jones, S., Saini, H. K., van Dongen, S., & Enright, A. J. (2008). miRBase: Tools for microRNA genomics. Nucleic Acids Research, 36, D154-D158.
13. Mizuno, Y., Yagi, K., Tokuzawa, Y., Kanesaki-Yatsuka, Y., Suda, T., Katagiri, T., et al. (2008). miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochemical and Biophysical Research Communications, 368(2), 267-272.
14. Luzi, E., Marini, F., Sala, S. C., Tognarini, I., Galli, G., & Brandi, M. L. (2008). Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. Journal of Bone and Mineral Research, 23(2), 287-295.
15. Sugatani, T., & Hruska, K. A. (2007). MicroRNA-223 is a key factor in osteoclast differentiation. Journal of Cellular Biochemistry, 101(4), 996-999.
16. Itoh, T., Nozawa, Y., & Akao, Y. (2009). MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. Journal of Biological Chemistry, 284(29), 19272-19279.
17. Mateescu, B., Batista, L., Cardon, M., Gruosso, T., de Feraudy, Y., Mariani, O., et al. (2011). miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nature Medicine, 17(12), 1627-1635.
18. Hao, J., Zhang, S., Zhou, Y., Liu, C., Hu, X., & Shao, C. (2011). MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochemical and Biophysical Research Communications, 406(4), 552-557.
19. Lu, J., Wen, M., Huang, Y., He, X., Wang, Y., Wu, Q., et al. (2013). C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics, 8(6), 571-583.
20. Li, D., Liu, X., Lin, L., Hou, J., Li, N., Wang, C., et al. (2011). MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. Journal of Biological Chemistry, 286(42), 36677-36685.
21. Coronnello, C., Benos, P. V., & Comi, R. (2013). Combinatorial microRNA target prediction tool. Nucleic Acids Research, 41, W159-W164.
22. John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004). Human MicroRNA targets. PLoS Biology, 2(11), e363.
23. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003). Prediction of mammalian microRNA targets. Cell, 115(7), 787-798.
24. Megraw, M., Sethupathy, P., Corda, B., & Hatzigeorgiou, A. G. (2007). miRGen: A database for the study of animal microRNA genomic organization and function. Nucleic Acids Research, 35, D149-D155.
25. Alexiou, P., Vergoulis, T., Gleditzsch, M., Prekas, G., Dalamagas, T., Megraw, M., et al. (2010). miRGen 2. 0: A database of microRNA genomic information and regulation. Nucleic Acids Research, 38, D137-D141.
26. Jones, K. B., Salah, Z., Del Mare, S., Galasso, M., Gaudio, E., Nuovo, G. J., et al. (2012). miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Research, 72(7), 1865-1877.
27. Hurteau, G. J., Carlson, J. A., Spivack, S. D., & Brock, G. J. (2007). Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Research, 67(17), 7972-7976.
28. Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., et al. (2008). A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Research, 68(19), 7846-7854.
29. Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9(6), 582-589.
30. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593-601.
31. Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry, 283(22), 14910-14914.
32. Park, S. M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & Development, 22(7), 894-907.
33. Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., Qian, D., et al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 138(3), 592-603.
34. Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology, 11(12), 1487-1495.
35. Iliopoulos, D., Lindahl-Allen, M., Polytarchou, C., Hirsch, H. A., Tsichlis, P. N., & Struhl, K. (2010). Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Molecular Cell, 39(5), 761-772.
36. Schickel, R., Park, S. M., Murmann, A. E., & Peter, M. E. (2010). miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Molecular Cell, 38(6), 908-915.
37. Chang, C. J., Chao, C. H., Xia, W., Yang, J. Y., Xiong, Y., Li, C. W., et al. (2011). p53 Regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology, 13(3), 317-323.
38. Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y. J., Volinia, S., et al. (2011). p53 Regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. Journal of Experimental Medicine, 208(5), 875-883.